Effect of hyoscine butylbromide on cervical dilation during labor


Department of Gynecology and Obstetrics of the “Dr. José Eleuterio González” University Hospital of the Autonomous University of Nuevo León, Mexico

Received 5 June 2014; accepted 25 November 2014
Available online 7 February 2015

KEYWORDS
Labor; Obstetrics; Oxytocics

Abstract

Objective: To compare the effects of intravenous hyoscine butylbromide versus placebo on the duration of labor in term pregnancies.

Materials and methods: 86 patients were selected and randomly assigned to receive intravenous hyoscine butylbromide (20 mg twice) (n = 43) or an intravenous placebo (saline solution 10 cc) (n = 43). We evaluated maternal adverse effects, effects on neonatal Apgar score, cervical dilatation 1 h after drug administration and the interval between the onset of labor and delivery.

Results: No significant differences were observed in the duration of phases of labor between the two groups. No significant differences were found between the groups in Apgar scores at 1 and 5 min. No maternal adverse effects were observed or reported due to the use of hyoscine butylbromide or the placebo. On the first phase of primigravidas it shortens the first labor phase up to 159.1 ± 84 min vs. the control group (p = 0.002).

Conclusion: Hyoscine butylbromide oxytocin shortens the duration of labor in term primigravida pregnancies. No side effects were reported.

© 2014 Universidad Autónoma de Nuevo León. Published by Masson Doyma México S.A. All rights reserved.

Introduction

Labor is a sequential physiological event. It integrates changes that will take place in the myometrium, decidua and cervix, which occur over a period of days, or even weeks. Biochemical changes appear before the onset of uterine contractions and cervical dilatation.¹ Labor at term, supposes the liberation of inhibitor factors which affect pregnancy and the myometrium, which sets off an active process through uterine stimulators.² Different substances
interact during labor, like prostaglandins (PG), estrogens and oxytocin, among others.

It was customary to follow the natural evolution of labor without the application of any method to accelerate it (passive handling of labor), either that or with the use of medications which accelerate it (active handling of labor).\footnote{1}

In the beginning of the 20th century, in 1906, the first uterotonic was discovered, oxytocin. It was not until 1911 when its implementation began to accelerate labor;\footnote{2} Oxytocin is a cyclic nonapeptide obtained through chemical synthesis. Its synthetic form is identical to that of a hormone stored in the posterior hypophysis, it stimulates the smooth muscle of the uterine strongly toward the end of the pregnancy, during labor and immediately after childbirth. During this phase, oxytocin receptors in the myometrium increase. This is a fast-acting hormone, with a latent period of under a minute after intravenous application and between 2 and 4 min after intramuscular injection.\footnote{3} In the active phase of the first period of labor, oxytocin is commonly used, in patients who require it in order to cause uterine contractions and to regularize its frequency.\footnote{4}

In some countries, in addition to the above, other medications have been used to shorten labor, such as drotaverin and hyoscine N-butylbromide (BBH).\footnote{5} This is part of a group of scopolamine derivatives, which are muscarinic antagonists and have antispasmodic effects. It inhibits cholinergic activity in abdominal and pelvic parasympathetic lymph nodes, having an effect on the smooth muscle of the digestive tract, urinary, biliary, female sexual organ and especially over the uterine-cervical plexus,\footnote{6} which explains its effect in cervical dilatation. However, this has not yet been clearly stated.\footnote{7}

This medication does not have effects over uterine contractility; it does not go through the blood–brain barrier and its fixation to proteins is very low, with a very quick distribution; after intravenous administration the time of action is around 10 min, with a peak from 20 to 60 min and an average life ranging from 4 to 5 h.\footnote{8} Its main mode of excretion is renal. No adverse effects during pregnancy or lactation have been proven; however, its use is recommended with caution under the first trimester. Side effects include: dry mouth, facial flushing, intermittent loss of accommodation reflexes, urinary retention and constipation.\footnote{9}

There have been few studies in which the use of BBH was evaluated to shorten labor. These have reported the reduction of labor time compared to the control group which received placebo,\footnote{10} and one study compared its effectiveness versus oxytocin.\footnote{11} The objective of our study was to compare the efficacy and safety of BBH versus placebo during labor.

Materials and methods

A randomized experimental study was designed in which patients older than 18 years were included, with a term pregnancy (37–42 weeks), independent from the parity with cephalic presentation, with a clinically adequate pelvis for labor, where there was no evidence of macrosomia (estimated fetal weight over 4000 g) and who were in the first period of labor in the active phase (dilation of 4 cm or more) with regular uterine activity (3–4 contractions in 10 min). We excluded all patients who needed to complete childbirth abdominally due to different causes.

Patients who were eligible for this study were chosen randomly to receive active treatment with BBH versus a placebo using a sampling of two proportions, in an infinite population, with a potency of 90% to detect the difference of 30% among the study groups; a statistically significant level of 0.05 was established. Over these premises a sample size of 40 patients per group was calculated.

The study included a total of 86 women who met the inclusion criteria and who went to the Emergency Service of the “Dr. José E. González” University Hospital for the resolution of their pregnancy between June 2009 and July 2010. All patients signed an informed consent.

The patients were randomly distributed into one of the two groups: the cases group, with 43 patients who were administered 20 mg of BBH (diluted in 9 ml of saline solution) intravenously on two occasions with an interval of 1 h, and the control group with 43 patients who were administered a placebo (10 ml of saline solution) at a similar dosage and interval. After every dose, fetal and maternal cardiac frequency monitoring was performed and patients were questioned about side effects. Labor progress was evaluated in a conventional manner, monitoring the time of every period of labor, in addition to the events occurring during its evolution (spontaneous rupture of membranes, analgesia, forceps application, etc.). Also weight at birth, Apgar and Capurro were evaluated. Maternal and fetal complications were evaluated (uterine atony, vaginal and perineal tears, etc.) after childbirth. Central tendency measurements were utilized and the duration of every period of labor was determined.

The differences between groups were compared with \( \chi^2 \) or Fisher’s exact test in the case of categorical variables and with the Student’s \( t \)-test for continuous variables.

### Table 1: Comparison of the characteristics of both groups.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>BBH</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>25.37 ± 6.98</td>
<td>25.65 ± 6.555</td>
<td>0.848</td>
</tr>
<tr>
<td>Nulliparous</td>
<td>13 (30.23%)</td>
<td>12 (27.9%)</td>
<td>0.499</td>
</tr>
<tr>
<td>Multiparous</td>
<td>30 (69.77%)</td>
<td>31 (72.1%)</td>
<td>0.499</td>
</tr>
<tr>
<td>Uterine fundus (cm)</td>
<td>32.72 ± 1.821</td>
<td>32.58 ± 1.845</td>
<td>0.726</td>
</tr>
<tr>
<td>Estimated fetal weight (g)</td>
<td>3220.93 ± 255.004</td>
<td>3228.58 ± 217.226</td>
<td>0.881</td>
</tr>
<tr>
<td>Johnson method (g)</td>
<td>3262.588 ± 294.40</td>
<td>3250.325 ± 292.241</td>
<td>0.847</td>
</tr>
</tbody>
</table>
Results

A total of 90 patients were included in the study. Of these, we discarded two patients from the case group and two from the control group, because it became necessary for them to have an abdominal birth. The cervical conditions of the placebo group upon entry were: dilation of 5.6 ± 1.5 cm, 73 ± 11% effacement and Bishop Index of 8.8 ± 1.2. And in the BBH group they were: dilation of 5.2 ± 1.3 cm, 72 ± 11% effacement and Bishop Index of 8.6 ± 1.2. Upon comparison of these variables, there was no statistically significant difference, which indicates that these two groups were homogenous (Table 1).

Regarding the results of the duration of labor, the first period of labor, evaluated in minutes, was 139.93 ± 92.48 in the placebo group versus 151.186 ± 84.6 in the BBH group (p = NS). The second period of labor had a duration of 15.5 ± 9.33 min in the first group and 13.18 ± 6.35 min in the second (p = NS). Finally, the third period registered a time of 6.4 ± 3.2 min in the placebo group and 6.5 ± 3.7 min in the BBH group. We were unable to find a statistically significant difference (Table 2).

Upon separating the groups by number of pregnancies, we found that the BBH group had a 159.1 ± 84 min time for the first phase of labor, with significant difference of p = 0.002 compared to the control group (262.5 ± 92 min).

Concerning the perinatal results, we observed a fetal weight of 3248 ± 374 g, a length of 50.7 ± 1.9 cm and 39.14 ± 1.2 Capurro weeks in the placebo group, and a fetal weight of 3185.5 ± 397 g, a length of 50.7 ± 1.7 cm and 38.9 ± 1.1 Capurro weeks in the BBH group. We were unable to find a statistically significant difference. Concerning the condition of the babies immediately after birth, we reported an Apgar score at the first minute of 8.2 ± 0.6 and 9.1 ± 0.4 at 5 min in the control group, and 8.2 ± 0.4 at the first minute and 9 ± 0 at 5 min in the BBH group. We were unable to find a statistically significant difference (Table 3).

Discussion

Previous studies performed with BBH have reported results which vary from no difference in cervical dilation time to decreases greater than 2 h. Aggarwal et al. performed a study in which they found that in addition to a 35.6% diminishment in the perception of pain during labor due to the use of intravenous BBH, the first period of labor was reduced in a significant way, from 8 h 16 min in the control group, to 3 h 46 min in the BBH group. Samals et al. concluded that using intravenous BBH, at a dose of 20 mg, was able to diminish the effort of labor by up to 32%.

Other authors recently compared the use of this pharmacuetic to oxytocin without finding a statistically significant difference in the effort of labor, which is the reason the use of this medication should be considered as an option for primigravid patients which, for whatever reason, cannot receive oxytocin.

We can make a recommendation for the use of this pharmacuetic in patients with the results obtained by separately evaluating groups of primigravid and multigravid patients which received BBH vs. a placebo; with regard to the multiparous, there was no significant difference found between any of the groups.

Just like in other studies, our results show no adverse effects on the fetus, which were evaluated by the APGAR at 1 and 5 min.

Conclusions

Based on the results obtained in our investigation, we can conclude that although we were not able to prove a statistically significant decrease in the effort of labor in both groups, we did demonstrate that when the groups of primigravidas and multigravidas are compared separately, the primigravida BBH group showed a statistically significant difference, with a p of 0.002.

Based on the previous studies, we can make a recommendation for the use of BBH in primigravid patients, also demonstrating that the administration of this product is safe during pregnancy, since there were no adverse effects presented during its administration, or among the babies in all the studied population.

Table 2  Comparison in labor evolution.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>BBH</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st. period (min)</td>
<td>139.93 ± 92.484</td>
<td>151.186 ± 84.657</td>
<td>0.577</td>
</tr>
<tr>
<td>2nd. period (min)</td>
<td>15.581 ± 9.334</td>
<td>13.186 ± 6.351</td>
<td>0.167</td>
</tr>
<tr>
<td>3rd. period (min)</td>
<td>6.418 ± 3.265</td>
<td>6.581 ± 3.724</td>
<td>0.82</td>
</tr>
</tbody>
</table>

Table 3  Perinatal results.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>BBH</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal weight (g)</td>
<td>3248.139 ± 374.837</td>
<td>3185.518 ± 397.28</td>
<td>0.454</td>
</tr>
<tr>
<td>Size (cm)</td>
<td>50.720 ± 1.992</td>
<td>50.767 ± 1.776</td>
<td>0.908</td>
</tr>
<tr>
<td>Silverman</td>
<td>0 (100%)</td>
<td>0 (100%)</td>
<td>0</td>
</tr>
<tr>
<td>Apgar 1 min</td>
<td>8.209 ± 0.666</td>
<td>8.209 ± 0.406</td>
<td>0</td>
</tr>
<tr>
<td>Apgar 5 min</td>
<td>9.186 ± 0.444</td>
<td>9 ± 0</td>
<td>0.007</td>
</tr>
<tr>
<td>Capurro (weeks)</td>
<td>39.146 ± 1.273</td>
<td>38.986 ± 1.180</td>
<td>0.547</td>
</tr>
</tbody>
</table>
Effect of hyoscine butylbromide on duration of labor

Conflict of interest

The authors have no conflicts of interest to declare.

Funding

No financial support was provided.

References